Warfarin Sensitivity Genotyping
Introduction
August 2008
Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.
Our presenter for this program is Dennis O’Kane, Co-Director of the Nucleotide Polymorphism Laboratory, in the Division of Clinical Biochemistry and Immunology at Mayo Clinic. Dr. O’Kane will be discussing the use of Mayo’s warfarin sensitivity genotyping test and identification of patients at risk of warfarin associated bleeding.
Additional information on this topic is available in the August 2008 issue of the Communiqué.
Introduction |
Jump to section:
- Warfarin
- Warfarin Anticoagulation
- Warfarin
- Warfarin Monitoring
- Therapeutic Graph
- INR Variability in a 74 Year-old Male
- Warfarin and Bleeding Events
- Warfarin Metabolism
- Polymorphisms and Warfarin Sensitivity
- Polymorphisms and Warfarin Sensitivity
- Summary of Polymorphisms and Warfarin Pharmacokinetics5
- CYP2C9 Association Study
- PGx-Guided Warfarin Dosing7
- Warfarin Pharmacodynamics
- Polymorphisms and Warfarin Sensitivity
- VKORC1 Promoter Polymorphism6
- CYP2C9 and VKORC1 Interaction8
- Genotype-guided Warfarin Dosing9
- Genotype-guided Dosing
- Summary
- Orthopedic Algorithm10
- Significant Warfarin Drug Interactions
- Differential Effect of Drugs
- Patient Case: Rapidly Increasing INR
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document